Plant · Scientific monograph
Silybum marianum
Milk thistle / Silymarin
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Hepatic / Liver Mechanisms, Oxidative Stress Research, Cellular & Immune Studies, Xenobiotic Metabolism Research
Research overview
Historical use
Milk thistle has been used medicinally for over 2,000 years. Dioscorides (c. 77 CE) described it as a remedy for serpent bites. In medieval Europe it was widely cultivated in monastery gardens and prescribed by herbalists including John Gerard (1597) specifically for liver and gallbladder conditions. Nicholas Culpeper (1653) noted it 'opens obstructions of the liver and spleen.' The common name derives from the milky white variegation of the leaves, legendarily caused by drops of the Virgin Mary's milk. Introduced to North American settlers as a liver tonic and galactagogue.
Modern research context
Silymarin is the standard-of-care emergency treatment for Amanita phalloides poisoning, where intravenous silibinin (Legalon SIL) competitively blocks amatoxin hepatocyte uptake via OATP transporters, dramatically reducing mortality [1, 4]. A landmark 1989 RCT by Ferenci et al. (n=170) demonstrated significantly improved 4-year survival in alcoholic cirrhosis patients treated with silymarin 420 mg/day versus placebo [2]. A 2017 RCT in NAFLD (the SLIM trial, n=99) showed silibinin 94 mg twice daily significantly reduced ALT and AST versus placebo after 24 weeks [3]. A comprehensive 2018 narrative review confirms hepatoprotective, anti-fibrotic, and antioxidant mechanisms across viral hepatitis, NAFLD, drug-induced liver injury, and cirrhosis models [1]. Silymarin also shows emerging anticancer activity via cell cycle arrest (G1/S) and STAT3 inhibition in hepatocellular carcinoma cell lines, though human oncology data remain limited [4].
Adverse effects
Exceptionally well tolerated. Mild and transient GI effects (loose stools, nausea, bloating) in ~1% of users — attributed to bile-stimulating activity. Rare allergic reactions in Asteraceae-sensitive individuals. Mild laxative effect (bile flow stimulation). No significant hepatotoxicity, nephrotoxicity, or haematological effects documented in any clinical trial.
Contraindications
Known Asteraceae/Compositae allergy. Caution with hormone-sensitive conditions — silibinin has mild oestrogenic activity (binds ERα weakly); use cautiously in ER-positive breast cancer (evidence is mixed — silibinin may actually be anti-oestrogenic at pharmacological doses). Caution with drugs metabolised by CYP2C9, CYP3A4, and UGT1A1 (silymarin inhibits all three). Avoid very high doses in acute biliary obstruction.
Clinical and phytochemical data
Used part
Seed (achene; standardised silymarin complex from seed extract)
Primary active compounds
Silibinin A and B (primary flavonolignans; most pharmacologically active; also called silybin)
Isosilybin A and B (diastereomers of silibinin)
Silydianin
Silychristin and isosilychristin
Taxifolin (dihydroquercetin; flavonoid precursor to lignan formation)
Fatty acids: linoleic acid (60%), oleic acid (30%) in seed oil
Mechanism of action
Silibinin competitively inhibits uptake of hepatotoxins (amatoxins, phalloidin, microcystins) via hepatic OATP1B3 (organic anion-transporting polypeptide), preventing cellular uptake — the mechanism behind its antidote role in Amanita poisoning. Potent antioxidant via Nrf2/HO-1 activation, increasing glutathione, superoxide dismutase, and catalase. Inhibits NF-κB, reducing hepatic stellate cell activation and TGF-β1-driven collagen synthesis (anti-fibrotic). Promotes hepatocyte regeneration by stimulating RNA polymerase I and ribosomal RNA synthesis. Inhibits CYP2E1-mediated oxidative metabolism — reducing reactive metabolite formation from alcohol and hepatotoxic drugs. Anti-tumour via EGFR inhibition, STAT3 suppression, and induction of apoptosis via caspase-3/7.
Pharmacokinetics
Absorption
Silybin (silibinin) reaches measurable concentrations in human plasma after oral milk thistle supplementation, although absolute bioavailability is low due to poor aqueous solubility and significant first-pass conjugation. In 9 healthy volunteers given standardised milk thistle extract thrice daily for 14 days, silybin A, silybin B, and isosilybin B were all detectable in plasma [1] — with silybin B as the dominant circulating diastereomer. In cancer patients receiving 200 mg milk thistle three times daily, maximum silybin plasma concentrations ranged from 0.025 to 0.257 µmol/L, highlighting wide inter-individual variability [2].
Distribution
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Silybin is highly lipophilic and extensively protein-bound to albumin in plasma. The low systemic exposure following oral dosing suggests distribution is predominantly to the gut wall and liver — the intended target organ for hepatoprotective effects — rather than to systemic tissues. No formal volume-of-distribution data have been reported in humans.
Metabolism
The primary metabolic route for silybin in humans is Phase II conjugation: glucuronidation and sulfation produce silybin glucuronide and silybin sulfate as the predominant circulating forms. Despite potent in vitro inhibition of CYP3A4 and UGT1A1 by silybin, a 14-day clinical study in 9 healthy volunteers found no significant effect on the activity of CYP1A2, CYP2C9, CYP2D6, or CYP3A4/5 when measured by probe drugs [1]. Similarly, in cancer patients, silybin plasma concentrations were too low to significantly affect irinotecan (a CYP3A4/UGT1A1 substrate) disposition [2], consistent with the concentration–effect discordance between in vitro and in vivo data for this compound.
Excretion
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Silybin and its conjugates are eliminated primarily in bile and faeces, consistent with its hepatic extraction and lipophilic character. Minor urinary excretion of glucuronide conjugates occurs. Specific elimination half-life data from human PK studies are not available in the published literature due to the challenges of measuring the low plasma concentrations achieved after standard oral dosing.
Safety and interactions
Drug interactions
Indinavir and HIV antiretrovirals (CYP3A4 substrates) — silibinin inhibition may increase plasma levels; monitor. Irinotecan (chemotherapy) — UGT1A1 inhibition increases active SN-38 metabolite; toxicity risk; consult oncologist. Warfarin — CYP2C9 inhibition possible; monitor INR. Metronidazole and other hepatically metabolised antibiotics — potential interaction. Oestrogen-containing contraceptives — theoretical oestrogenic interaction; not confirmed clinically at standard doses.
Toxicity
LD50 >5,000 mg/kg in rodents (oral). No serious adverse events have been reported in any published clinical trial; the available evidence is insufficient to establish long-term safety beyond the studied durations. IV silibinin (Legalon SIL) for Amanita poisoning: transient mild haemolysis reported at very high parenteral doses. No carcinogenicity, mutagenicity, or reproductive toxicity documented.
Special precautions
Pregnancy
Insufficient human safety data. Mild oestrogenic activity — avoid high-dose supplemental use during pregnancy. Traditional use as a galactagogue (milk promoter) historically considered safe at low doses.
Lactation
Traditionally used to promote milk production. Limited safety data on neonatal exposure via breast milk at supplemental doses. Culinary use considered safe; avoid concentrated extracts.
Hepatic impairment
The primary indication. Hepatoprotective and regenerative at therapeutic doses. Consider dose reduction in severe cirrhosis (reduced first-pass metabolism increases plasma exposure). Generally well tolerated even in advanced liver disease.
Renal impairment
Minor renal excretion of metabolites. No specific contraindication has been identified. No formal dose adjustment guidelines have been established. At standard doses, no clinically significant adverse renal outcomes have been reported in available data; monitoring is reasonable in severe impairment.
Sources and references
- [1] - Abenavoli L, Izzo AA, Milić N, Cicala C, Santini A, Capasso R., "Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases.", Phytother Res, 2018, PMID: 29925024
- [2] - Ferenci P, Dragosics B, Dittrich H et al., "Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver.", J Hepatol, 1989, PMID: 2671116
- [3] - Wah Kheong C, Nik Mustapha NR, Mahadeva S., "A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis.", Clin Gastroenterol Hepatol, 2017, PMID: 28521691
- [4] - Gillessen A, Schmidt HH., "Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review.", Adv Ther, 2020, PMID: 32045808
- [5] - Takahashi N, Ookawara S, Morishita Y., "Improved pharmacokinetics of silybin (silibinin) with sodium silibinin-phosphatidylcholine complex administration.", Drug Metab Pharmacokinet, 2016, PMID: 26830274